Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes

Cardiovasc Res. 2022 Jan 7;118(1):196-211. doi: 10.1093/cvr/cvab013.

Abstract

Aims: The aim of this study was to identify the molecular mechanism for hyperglycaemia-induced metabolic memory in endothelial cells (ECs), and to show its critical importance to development of cardiovascular dysfunction in diabetes.

Methods and results: Hyperglycaemia induces increased nuclear factor-κB (NF-κB) signalling, up-regulation of miR-27a-3p, down-regulation of nuclear factor erythroid-2 related factor 2 (NRF2) expression, increased transforming growth factor-β (TGF-β) signalling, down-regulation of miR-29, and induction of endothelial-to-mesenchymal transition (EndMT), all of which are memorized by ECs and not erased when switched to a low glucose condition, thereby causing perivascular fibrosis and cardiac dysfunction. Similar metabolic memory effects are found for production of nitric oxide (NO), generation of reactive oxygen species (ROS), and the mitochondrial oxygen consumption rate in two different types of ECs. The observed metabolic memory effects in ECs are blocked by NRF2 activator tert-butylhydroquinone and a miR-27a-3p inhibitor. In vivo, the NRF2 activator and miR-27a-3p inhibitor block cardiac perivascular fibrosis and restore cardiovascular function by decreasing NF-κB signalling, down-regulating miR-27a-3p, up-regulating NRF2 expression, reducing TGF-β signalling, and inhibiting EndMT during insulin treatment of diabetes in streptozotocin-induced diabetic mice, whereas insulin alone does not improve cardiac function.

Conclusions: Our data indicate that disruption of hyperglycaemia-induced EC metabolic memory is required for restoring cardiac function during treatment of diabetes, and identify a novel molecular signalling pathway of NF-κB/miR-27a-3p/NRF2/ROS/TGF-β/EndMT involved in metabolic memory.

Keywords: (Smad2 and Smad3); Cardiac perivascular fibrosis; Diabetes mellitus; EndMT; Endothelial cell; Metabolic memory; NF-κB (p65); NRF2; TGF-β; miR-27a-3p; miR-29.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism*
  • Cells, Cultured
  • Diabetic Cardiomyopathies / drug therapy
  • Diabetic Cardiomyopathies / metabolism*
  • Diabetic Cardiomyopathies / pathology
  • Diabetic Cardiomyopathies / physiopathology
  • Disease Models, Animal
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelial Cells / pathology
  • Energy Metabolism* / drug effects
  • Epithelial-Mesenchymal Transition* / drug effects
  • Fibrosis
  • Humans
  • Hydroquinones / pharmacology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • NF-E2-Related Factor 2 / agonists
  • NF-E2-Related Factor 2 / metabolism
  • NF-kappa B / metabolism
  • Reactive Oxygen Species / metabolism
  • Signal Transduction
  • Transforming Growth Factor beta / metabolism

Substances

  • Blood Glucose
  • Hydroquinones
  • MIRN27 microRNA, human
  • MicroRNAs
  • Mirn27 microRNA, mouse
  • NF-E2-Related Factor 2
  • NF-kappa B
  • NFE2L2 protein, human
  • Nfe2l2 protein, mouse
  • Reactive Oxygen Species
  • Transforming Growth Factor beta
  • 2-tert-butylhydroquinone